(Women &Infants Hospital) A team of researchers from Women &Infants Hospital of Rhode Island commanded a national stage to present the results of a study evaluating the use of sentinel lymph node dissection in women with vulvar malignancies, and then follow the patients for complications and recurrence.
Periodic gynecologic oncology campaigns in settings otherwise lacking local capacity to perform advanced surgery are a feasible model to create access and build local capacity. Strong local collaboration is essential. Future strategies to increase impact include recruitment of more gynecologic oncologists to increase service and training availability.
Acta Obstetricia et Gynecologica Scandinavica,Volume 0, Issue ja, -Not available-.
Objective: Minimally invasive inguinal lymphadenectomy is progressively emerging as an appealing strategy in patients with vulvar cancer. At the same time, sentinel node biopsy (SNB) is currently recognized as standard of care in patients with early stage vulvar cancer (ESVC). Therefore, the integration of minimally invasive approaches and SNB appears as an intriguing horizon.
Authors: Buchanan T, Mutch D
INTRODUCTION: Although a relatively uncommon disease, the treatment of vulvar cancer has changed considerably over the years and has been under considerable focus due to its past overtreatment and apparent increase in incidence. The purpose of this review is to describe the recommended management of the most commonly encountered vulvar carcinomas based on the most recent available literature. Areas covered: The clinical environment of squamous cell vulvar cancers are illustrated in order to describe the potential pitfalls and limitations of treatment. Then, by examining publish…
Adults up to age 45 can now be vaccinated against human papillomavirus (HPV), reducing their chances of getting cervical, oral and other cancers.
The Food and Drug Administration (FDA) announced Friday that Gardasil 9, a vaccine that works against nine different types of HPV, is now approved for both men and women between the ages of 27 and 45. Previously, it was approved only for those between the ages of nine and 26, and recommended for all children at age 11 or 12.
“Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” Dr. Peter M…
CONCLUSION: GATA2 deficiency causes immunodeficiency in young women, and patients with early-onset HPV-related disease, a family or personal history of leukemia, recurrent infection, or immune irregularities should be screened. Health care providers for these women are often obstetrician-gynecologists, who can provide diagnosis, treatment, referral, and prevention of HPV-related diseases.
PMID: 30303925 [PubMed – as supplied by publisher]
Condition: Vulvar Cancer, G9a Protein Intervention: Biological: G9a protein Sponsors: Far Eastern Memorial Hospital; Gynecologic Oncology Group Recruiting